Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 501–600 of 1,000
Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
Zhang, X., Huang, H., Zhang, G., Li, D., Wang, H., & Jiang, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00903 · Cited by 21
Lemieszek, M. K., Rzeski, W., Golec, M., Maćkiewicz, B., Zwoliński, J., Dutkiewicz, J. K., & Milanowski, J. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110416 · Cited by 20
Caro, F. M., Buendía-Roldán, I., Noriega, L., Alberti, M. L., Amaral, A. F., Arbo, G., Auteri, S. J., Bermúdez, A., Curbelo, P., Verduzco, M. D. J. D., et al. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.04.007 · Cited by 20
Self-citationKanaan, R., & Strange, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0061-2017 · Cited by 23
Paulín, F., Babini, A. M., Mamani, M. N., Mercado, J. F., & Caro, F. M. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002162 · Cited by 22
Cottin, V. (2013) · European Respiratory Journal · doi:10.1183/09031936.00024113 · Cited by 21
Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106551 · Cited by 19
Walters, T. M., Leong, M. C. H., Montesi, S. B., Ryerson, C. J., & Khor, Y. H. (2025) · European Respiratory Review · doi:10.1183/16000617.0238-2024 · Cited by 20
Τzouvelekis, Α., Tzilas, V., Papiris, S. A., Aidinis, V., & Bouros, D. E. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.12.002 · Cited by 20
Lv, Y., Cai, G.-F., Zeng, P.-P., Dhlamini, Q., Chen, L.-F., Chen, J., Lyu, H., Mohammadi, M. M., Ahmadvand, N., Bellusci, S., et al. (2022) · Cells · doi:10.3390/cells11152396 · Cited by 22
Recent Advances in Idiopathic Pulmonary Fibrosis
Park, S. H., & Lee, E. J. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.74.1.1 · Cited by 19
Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation
Richeldi, L. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201504-210aw · Cited by 21
Self-citationRecent Treatments of Interstitial Lung Disease with Systemic Sclerosis
Yasuoka, H. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23315 · Cited by 19
Vaszar, L. T., Larsen, B. T., Swanson, K. L., Ryu, J. H., & Tazelaar, H. D. (2017) · Respirology · doi:10.1111/resp.13223 · Cited by 20
Hammond, M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2453-6 · Cited by 20
Carrington, R., Jordan, S., Wong, Y. J., Pitchford, S. C., & Page, C. P. (2021) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2021.107057 · Cited by 21
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98161-y · Cited by 21
Ruaro, B., Gandin, I., Pozzan, R., Tavano, S., Bozzi, C., Hughes, M., Kodric, M., Cifaldi, R., Lerda, S., Confalonieri, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020307 · Cited by 19
MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1.
Zhuang, Y., Dai, J., Wang, Y., Zhang, H., Li, X., Wang, C., Cao, M., Liu, Y., Cai, H., Zhang, D., et al. (2016) · Europe PMC (PubMed Central) · Cited by 20
Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice
Susutlertpanya, W., Wakuda, H., Otani, N., Kuramoto, T., Li, L., Kuranari, M., Sekiguchi, A., Kudo, H., Uchida, T., Imai, H., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.014 · Cited by 20
Zhu, Y., Zheng, X., Wang, C., Sun, X., Sun, H., Ma, T., Li, Y., Liu, K., Chen, L., & Ma, X. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115254 · Cited by 19
Wilson, K. C., & Raghu, G. (2015) · European Respiratory Journal · doi:10.1183/13993003.01335-2015 · Cited by 19
Self-citationSuzuki, T., Hozumi, H., Miyashita, K., Kono, M., Suzuki, Y., Karayama, M., Furuhashi, K., Hasegawa, H., Fujisawa, T., Enomoto, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88718-2 · Cited by 20
Xu, L., Wang, F., & Luo, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1019915 · Cited by 20
Gracillin relieves pulmonary fibrosis by suppressing the STAT3 axis
Xie, M., Yang, L., Cheng, J., Qu, H., Gu, Y.-T., Ding, C., Xu, X., Zhao, C., Huang, X., & Wang, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116704 · Cited by 20
Wang, X., Goyal, M., Gadhave, D. G., & Gupta, V. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105615 · Cited by 19
The safety of new drug treatments for idiopathic pulmonary fibrosis
Fletcher, S., Jones, M. G., Spinks, K., Sgalla, G., Marshall, B. G., Limbrey, R., & Richeldi, L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1218470 · Cited by 20
Self-citationSpagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
Treatment of acute exacerbations of interstitial lung disease
Azadeh, N., Moua, T., Baqir, M., & Ryu, J. H. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1446831 · Cited by 19
Imaging biomarkers and staging in IPF
Walsh, S. L. F. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000507 · Cited by 19
Current and Future Idiopathic Pulmonary Fibrosis Therapy
Richeldi, L., Baldi, F., Pasciuto, G., Macagno, F., & Panico, L. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.006 · Cited by 18
Self-citationDy, G. K., Prasad, D., Kumar, P. K. M., Attwood, K. M., & Adjei, A. A. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.019 · Cited by 22
Rahaghi, F., Belperio, J. A., Fitzgerald, J., Gulati, M., Hallowell, R. W., Highland, K. B., Huie, T. J., Kim, G. H. J., Kolb, M. R. J., Lasky, J. A., et al. (2021) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/11795484211006050 · Cited by 18
A novel prognostic signature for idiopathic pulmonary fibrosis based on five-immune-related genes
Qiu, L., Gong, G., Wu, W., Li, N., Li, Z., Chen, S., Li, P., Chen, T., Zhao, H., Hu, C., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4545 · Cited by 19
Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-01940-y · Cited by 20
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Sakao, S., & Tatsumi, K. (2012) · Oncology Letters · doi:10.3892/ol.2012.872 · Cited by 18
Long-term management of patients with end-stage lung diseases
Briganti, D. F., & D’Ovidio, F. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.007 · Cited by 19
Segurança e tolerabilidade de Nintedanibe em pacientes com fibrose pulmonar idiopática no Brasil
Pereira, C. A. D. C., Martínez, J. A. B., Baldi, B. G., Jezler, S. F. D. O., Rubin, A. S., Rufino, R., Zonzin, G., Quaresma, M., Trampisch, M., & Rabahi, M. F. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20180414 · Cited by 25
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Schmid, U., Weber, B., Sarr, C., & Freiwald, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01598-0 · Cited by 18
Resolving the Scar of Pulmonary Fibrosis
Downey, G. P. (2011) · New England Journal of Medicine · doi:10.1056/nejme1108558 · Cited by 20
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Maher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Blahova, Z., Wachtlin, D., Diefenbach, C., et al. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000325 · Cited by 17
Self-citationAronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 20
Acute exacerbation of interstitial lung disease in the intensive care unit
Charokopos, A., Moua, T., Ryu, J. H., & Smischney, N. J. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i1.22 · Cited by 20
Choi, M. G., Choi, S. M., Lee, J. H., Kim, J., & Song, J. W. (2022) · Respiratory Research · doi:10.1186/s12931-022-02273-6 · Cited by 17
Shu, Y., Xue, S., Wang, T., Gao, R., Zeng, H., Wang, Q., & Jia, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1086214 · Cited by 20
PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02582-4 · Cited by 19
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
Nintedanib: a new treatment for idiopathic pulmonary fibrosis
Cottin, V. (2015) · Clinical Investigation · doi:10.4155/cli.15.27 · Cited by 18
Lee, J. S., & Fischer, A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1139454 · Cited by 18
Antioxidants in respiratory diseases: Basic science research and therapeutic alternatives
Alvarado, A., & Arce, I. (2016) · Clinical Research and Trials · doi:10.15761/crt.1000163 · Cited by 21
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 18
Treatment of Idiopathic Pulmonary Fibrosis
Abuserewa, S. T. H., Duff, R., & Becker, G. (2021) · Cureus · doi:10.7759/cureus.15360 · Cited by 18
Baroke, E., Gauldie, J., & Kolb, M. R. J. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.838015 · Cited by 18
Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats
de Raaf, M. A., Herrmann, F. E., Schalij, I., de Man, F. S., Noordegraaf, A. V., Guignabert, C., Wollin, L., & Bogaard, H. J. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00656.2015 · Cited by 17
Recipient selection process and listing for lung transplantation
Verleden, G. M., Dupont, L., Yserbyt, J., Schaevers, V., Raemdonck, D. E. V., Neyrinck, A., & Vos, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.90 · Cited by 19
Nintedanib for treating idiopathic pulmonary fibrosis
Hayton, C., & Chaudhuri, N. (2016) · British Journal of Healthcare Management · doi:10.12968/bjhc.2016.22.5.250 · Cited by 17
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Tu, H., Han, L. W., Hsu, J. C., Kamath, N., & Pan, L. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231181537 · Cited by 17
Liao, K., & Chen, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1309712 · Cited by 18
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit
Massoud, G., Parish, M. A., Hazimeh, D., Moukarzel, P., Singh, B., Vaught, K. C. C., Segars, J., & Islam, M. S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112423 · Cited by 17
Evidence from recent clinical trials in fibrotic interstitial lung diseases
Cottin, V., & Valenzuela, C. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001089 · Cited by 18
Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis
Hirasawa, Y., Abe, M., Terada, J., Sakayori, M., Suzuki, K., Yoshioka, K., Kawasaki, T., Tsushima, K., & Tatsumi, K. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101917 · Cited by 16
Erre, G. L., Sebastiani, M., Manfredi, A., Gerratana, E., Atzeni, F., Passiu, G., & Mangoni, A. A. (2021) · Drugs in Context · doi:10.7573/dic.2020-8-6 · Cited by 20
SHP2 : The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis
Chang, C., Lin, C., Chen, B.-C., Lin, P., & Chen, C. (2021) · IUBMB Life · doi:10.1002/iub.2559 · Cited by 18
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis
Sgalla, G., Comes, A., & Richeldi, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1921143 · Cited by 18
Self-citationPulmonary fibrosis, part II: state-of-the-art patient management
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312347 · Cited by 17
Transbronchial cryobiopsy in the diagnosis of interstitial lung disease: A cool new approach
Mikolasch, T., & Porter, J. C. (2014) · Respirology · doi:10.1111/resp.12320 · Cited by 16
Park, M. Y., Bae, S., Heo, J. A., Park, M., Kim, Y., Han, J., Jang, I., Yu, K., & Oh, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13518 · Cited by 15
Xu, D., Zhang, Y., Dai, J., Bai, Y., Xiao, Y., & Zhou, M. (2015) · Analytical Methods · doi:10.1039/c5ay01207d · Cited by 17
Clinical trials and tribulations--lessons from pulmonary fibrosis
Olson, A. L., Swigris, J. J., & Brown, K. K. (2012) · QJM · doi:10.1093/qjmed/hcs066 · Cited by 15
Self-citationOngoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways
Yu, H., Feng, Z., Lin, W., Yang, K., Liu, R., Li, J., Liu, X., Pei, M., & Yang, H. (2022) · Aging and Disease · doi:10.14336/ad.2021.1105 · Cited by 17
Zhang, Q., Li, G., Zhao, G., Yan, C., Lv, H., Fu, Y., Li, Y., & Zhao, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106779 · Cited by 17
Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation
Nicolay, N. H., Sommer, E., Perez, R. L., Wirkner, U., Bostel, T., Ho, A. D., Lahn, M. M. F., Debus, J., Saffrich, R., & Huber, P. E. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0686-1 · Cited by 16
Chan, P., Bax, L., Chen, C., Zhang, N., Huang, S., Soares, H. D., Rosen, G., & Abutarif, M. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12227 · Cited by 16
Kondoh, Y., Taniguchi, H., Kataoka, K., Furukawa, T., Shintani, A., Fujisawa, T., Suda, T., Arita, M., Baba, T., Ichikado, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193608 · Cited by 15
Shakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts
Oka, H., Ishii, H., Iwata, A., Kushima, H., Toba, S., Hashinaga, K., Umeki, K., Tokimatsu, I., Hiramatsu, K., & Kadota, J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.10.026 · Cited by 15
A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis
Moran‐Mendoza, O., Colman, R., Kalluri, M., Cabalteja, C., & Harle, I. A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1627204 · Cited by 15
López-Rodríguez, E., Gay-Jordi, G., Knudsen, L., Ochs, M., & Serrano‐Mollar, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.640020 · Cited by 19
Schmid, U., Weber, B., Magnusson, M. O., & Freiwald, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106369 · Cited by 15
New Approaches to Modulating Idiopathic Pulmonary Fibrosis
Gomer, R. H. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-013-0377-5 · Cited by 15
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 18
Iyer, S., Enman, M., Sahay, P., & Dudeja, V. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2355969 · Cited by 14
Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 15
Self-citationQiu, Y., & Ye, W. (2025) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_132_25 · Cited by 16
Health economic evaluation in idiopathic pulmonary fibrosis in France
Fanny, P., Cottin, V., Laura, C., Luciani, L., Lay, K. L., & Bénard, S. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1433143 · Cited by 15
Aschner, Y., Nelson, M., Brenner, M., Roybal, H. M., Beke, K. M., Meador, C., Foster, D. G., Correll, K. A., Reynolds, P. R., Anderson, K. C., et al. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00235.2019 · Cited by 15
Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
Hadda, V., & Guleria, R. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_90_20 · Cited by 14
Koga, S., Onishi, H., Masuda, S., Fujimura, A., Ichimiya, S., Nakayama, K., Imaizumi, A., Nishiyama, K., Kojima, M., Miyoshi, K., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101152 · Cited by 16
Inoue, Y., Suda, T., Kitamura, H., Okamoto, M., Azuma, A., Inase, N., Kuwana, M., Makino, S., Nishioka, Y., Ogura, T., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106574 · Cited by 16
Yoon, H., Lee, S. H., Ha, S., Ryu, J., & Song, J. W. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e257 · Cited by 17
Management of patients with fibrosing interstitial lung diseases
Morrow, L. E., Hilleman, D. E., & Malesker, M. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab375 · Cited by 15
Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., Yokomura, K., Fukada, A., Inoue, Y., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02062-1 · Cited by 15
Wu, X., Xiao, X., Chen, X., Yang, M., Hu, Z., Shuai, S., Fu, Q., Yang, H., & Du, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948101 · Cited by 16
Kagawa, K., Sato, S., Koyama, K., Imakura, T., Murakami, K., Yamashita, Y., Naito, N., Ogawa, H., Kawano, H., & Nishioka, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275987 · Cited by 14
Zhang, H., Fang, S., Wang, C., Wang, W., Wu, J., Wang, C., Xu, B., & Zhang, Y. (2015) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0057 · Cited by 14
Immunosuppressive Therapy for Autoimmune Lung Diseases
Meyer, K. C., & Bierach, J. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.07.001 · Cited by 14
Avdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.